Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10832

    +

    P1.11-031 - Cost effectiveness analysis between Gefitinib and Erlotinib in the treatment of advanced /metastatic Non small cell lung cancer in Thailand by Payer's perspective: Six years data follow up (ID 2219)

    09:30 - 09:30  |  Author(s): S. Jaruhathai
    • Abstract

    Background
    Lung cancer is the second most common cancer in Thailand. Oral TKI, Gefitinib and Erlotinib are available for second line and third line treatment in advanced non small cell lung cancer by registration Central Health Informatics for reimbursement. This study aims to compare cost-effectiveness between Erlotinib and Gefitinib by Payer’s perspective.

    Methods
    A retrospective observational study of Thai patients who were diagnosed advanced non small cell lung cancer and be registered for Oral TKI treatment in either line from 1st Jan 2006-31st Dec 2011. The demographic and clinical data were collected from registered database. The cost analysis data was from reimbursement system. It was analyzed in terms of the direct medical costs during on oral TKI and total direct medical costs through patient’s life time.

    Results
    Total 1,520 cases database were recruited for analysis. There were 572 and 948 patients in Gefitinib and Erlotinib group respectively. The mean age was 64.8±11.0 years. Most of patients (94.4%) were in ECOG 0-2. The mean overall survival was 15.1 months [95% CI 14.1-16.0]. The mean of the direct medical costs and total direct medical costs of Gefitinib were 623,204.80 baht and 738,441.30 baht, while Erlotinib group were 718,443.50 baht and 837,126.30 baht. The cost effectiveness ratio (CER) in term of overall survival were 581,883 baht per life year gain in Gefitinib group and 688,791.50 baht per life year gain in Erlotinib group.

    Conclusion
    This long term observational study shows that the effectiveness between Erlotinib and Gefitinib in Non Small Lung Cancer treatment were comparable. Nevertheless, Gefitinib is more cost saving than Erlotinib by payer’s perspective.